The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2024 | Assessing if a patient with DLBCL is responding to treatment using PET-CT and novel assays
Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, discusses the assessment of treatment response in patients with diffuse large B-cell lymphoma (DLBCL). He highlights the role of various assays and when they should be used to assess treatment efficacy and response. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
